Optinose reported Q3 2024 financial results and corporate updates today. Read more here: https://lnkd.in/eaKGkQ95. We will host a webcast at 8:00 a.m. ET that will be available live and for replay on our website https://lnkd.in/eMkyXxwT.
About us
We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.
- Website
-
http://www.optinose.com
External link for Optinose
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Yardley, PA
- Type
- Public Company
- Founded
- 2010
- Specialties
- Specialty Pharmaceuticals, Drug Development, ENT Therapy, Allergy Therapy, and Ear Nose Throat
Locations
-
Primary
Get directions
1020 Stony Hill Road
Suite 300
Yardley, PA 19067, US
-
Get directions
Berkeley House
Hunts Rise
South Marston, Wiltshire SN3 4TG, GB
-
Get directions
Oslo Innovation Center
Oslo, . Gaustedelleen 0349, NO
Employees at Optinose
Updates
-
Today we announced the publication of new peer-reviewed data from the ReOpen Program in the International Forum of Allergy & Rhinology. To learn more read here: https://bit.ly/3Zbt2lu
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery | Optinose
ir.optinose.com
-
Optinose reported Q2 2024 financial results and corporate updates today. Read more here: http://bit.ly/3WUy8kp. Leaders of our management team will host a webcast at 8:00 a.m. ET that will be available live and for replay on our website https://bit.ly/3UvqnjY
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights | Optinose
ir.optinose.com
-
Leaders of our management team will speak today at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ at 11:30 a.m. ET. A webcast of the presentation will be available live and for replay on our website https://bit.ly/3UvqnjY
Event Calendar | Optinose
ir.optinose.com
-
Optinose reported Q1 2024 financial results and corporate updates today. Read more here: https://bit.ly/3QIwr6l. Leaders of our management team will host a webcast at 10:00 a.m. ET that will be available live and for replay on our website https://bit.ly/3UvqnjY
-
-
Leaders of our management team will host an XHANCE Chronic Sinusitis Launch Update on April 25 at 10:00 a.m. ET. A webcast of the presentation will be available live and for replay on our website https://bit.ly/3UvqnjY
-
-
Leaders of our management will speak at the Needham Virtual Healthcare Conference on April 10 at 2:15 pm ET. A webcast of the presentation will be available on optinose.com https://bit.ly/43NUQwD
-
-
We are excited today to announce the US FDA approval of XHANCE as the first and only medication indicated for treatment of adults with chronic rhinosinusitis without nasal polyps. Chronic sinusitis is diagnosed in approximately 10 million outpatient visits, of which approximately 70% result in antibiotic prescriptions, and leads to more than 600,000 surgeries annually. Read more here: https://bit.ly/4aaiN34
-
-
Optinose reposted this
We reported our fourth quarter and full year 2023 financial results and corporate updates today. We will host a webcast at 8 am ET. Read all the details here: https://bit.ly/3wCqyAk
-
-
We reported our fourth quarter and full year 2023 financial results and corporate updates today. We will host a webcast at 8 am ET. Read all the details here: https://bit.ly/3wCqyAk
-